These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 10528290

  • 1. Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents.
    Bushnell DL, Madsen M, Kahn D, Nathan M, Williams RD.
    Nucl Med Commun; 1999 Oct; 20(10):875-81. PubMed ID: 10528290
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of metastatic bone disease with pentavalent 99Tc(m)-dimercaptosuccinic acid: a comparison with whole-body scanning and 4/24 hour quantitation of vertebral lesions.
    Sahin M, Basoglu T, Bernay I, Yapici O, Canbaz F, Yalin T.
    Nucl Med Commun; 2000 Mar; 21(3):251-8. PubMed ID: 10823327
    [Abstract] [Full Text] [Related]

  • 3. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by 18F-FDG PET/CT. The role of 99mTc-MDP.
    Pietrzak A, Czepczynski R, Wierzchoslawska E, Cholewinski W.
    Hell J Nucl Med; 2017 Mar; 20(3):237-240. PubMed ID: 29177262
    [Abstract] [Full Text] [Related]

  • 4. Detection of metastatic bone lesions in patients with prostate carcinoma: 99Tcm-monoclonal antibody imaging.
    Kiraç S, Duman Y, Cüreklibatur I, Yüksel D, Nazli O, Günaydin G, Taner M.
    Nucl Med Commun; 1997 Oct; 18(10):968-73. PubMed ID: 9392800
    [Abstract] [Full Text] [Related]

  • 5. Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan.
    Johns WD, Garnick MB, Kaplan WD.
    Clin Nucl Med; 1990 Jul; 15(7):485-7. PubMed ID: 2116949
    [Abstract] [Full Text] [Related]

  • 6. 99Tcm-MDP and 99Tcm-DPD in pathologic bone lesions. A visual and quantitative comparison.
    Lantto T, Vorne M, Mokka R, Vähätalo S.
    Acta Radiol; 1987 Jul; 28(5):631-3. PubMed ID: 2960361
    [Abstract] [Full Text] [Related]

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jul; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 8. 99Tcm-citrate: a new bone imaging radiopharmaceutical.
    Bhatnagar A, Mishra P, Sharma R, Chuttani K, Chakravarty K, Jain CM, Mondal A, Chopra MK, Gupta A.
    Nucl Med Commun; 1999 Nov; 20(11):1067-76. PubMed ID: 10572918
    [Abstract] [Full Text] [Related]

  • 9. Pentavalent 99Tcm-DMSA imaging in patients with bone metastases.
    Lam AS, Kettle AG, O'Doherty MJ, Coakley AJ, Barrington SF, Blower PJ.
    Nucl Med Commun; 1997 Oct; 18(10):907-14. PubMed ID: 9392790
    [Abstract] [Full Text] [Related]

  • 10. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.
    Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD.
    J Nucl Med; 2012 Nov; 53(11):1670-5. PubMed ID: 22984218
    [Abstract] [Full Text] [Related]

  • 11. Clinical evaluation of the bone marrow imaging agent 99Tcm-phytate in the detection of bone metastases.
    Chang CP, Liu RS, Yu SM, Wynchank S, Chu LS, Shiau HY, Cheng TC.
    Nucl Med Commun; 1996 Dec; 17(12):1030-4. PubMed ID: 9004298
    [Abstract] [Full Text] [Related]

  • 12. Clinical evaluation of a technetium-99m bone imaging agent based on the vicinal diphosphonate 1,2-diphosphonoethyleneglycol (DPEG).
    Pauwels EK, Camps JA, Blom J, Hermans J, Kelly JD, Cumming SA, Blackburn GM, Rashid A.
    Nucl Med Commun; 1985 Nov; 6(11):739-45. PubMed ID: 3831848
    [Abstract] [Full Text] [Related]

  • 13. The CT flare response of metastatic bone disease in prostate cancer.
    Messiou C, Cook G, Reid AH, Attard G, Dearnaley D, de Bono JS, de Souza NM.
    Acta Radiol; 2011 Jun 01; 52(5):557-61. PubMed ID: 21498309
    [Abstract] [Full Text] [Related]

  • 14. Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.
    Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.
    J Nucl Med; 2018 Sep 01; 59(9):1373-1379. PubMed ID: 29371410
    [Abstract] [Full Text] [Related]

  • 15. Comparison of 99Tcm-labelled MDP and DMAD bone scanning agents in patients with advanced breast cancer.
    Coleman RE, Meier CA, Rubens RD, Fogelman I.
    Nucl Med Commun; 1988 Jul 01; 9(7):481-5. PubMed ID: 3173907
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 99Tcm-MDP global skeletal uptake and markers of bone metabolism in patients with bone diseases.
    Rubini G, Lauriero F, Rubini D, D'Addabbo A.
    Nucl Med Commun; 1993 Jul 01; 14(7):567-72. PubMed ID: 8355916
    [Abstract] [Full Text] [Related]

  • 18. Relationship between 99Tcm-MDP uptake and bone mineral density in patients with prostatic carcinoma.
    Sundkvist GM, Nilsson M, Ahlgren L, Lilja B, Mattsson S, Birch-Iensen M, Abrahamsson PA.
    Nucl Med Commun; 1991 Jul 01; 12(7):629-36. PubMed ID: 1923154
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Discrepancy between clinical symptoms and Tc-99m MDP bone scan findings before and after strontium-89 therapy for metastatic bone pain of prostate carcinoma.
    Sun SS, Tsai SC, Hsieh JF, Lee JK, Kao CH.
    Clin Nucl Med; 2001 Feb 01; 26(2):167-9. PubMed ID: 11201488
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.